GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Bcl2 | decreases expression | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Cytarabine results in decreased expression of BCL2 mRNA; Cytarabine results in decreased expression of BCL2 protein | PMID:1450413 PMID:16129037 PMID:17490525 PMID:9295281 | Bcl2 | increases degradation | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Cytarabine results in increased degradation of BCL2 protein | PMID:12853972 | Bcl2 | multiple interactions | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; BCL2 protein inhibits the reaction [Cytarabine results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Cytarabine results in increased degradation of PARP1 protein]; edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein] | PMID:21182165 PMID:8840993 PMID:9295281 | |
Go Back to source page | Continue to Ontology report |